Organigram Global (NASDAQ:OGI) announced today that its shareholders have granted overwhelming approval for the acquisition of Germany’s Sanity Group.
The transaction, which includes a strategic private placement from BT DE Investments, a subsidiary of British American Tobacco (BAT), received an affirmative vote of 93% from disinterested shareholders.
The approval authorizes the issuance of up to 96,287,602 common shares to satisfy both the acquisition and the related BAT financing.
The deal is expected to close in April 2026, pending customary closing conditions and the finalization of senior secured credit facilities with ATB Financial.
Organigram has already secured the necessary foreign direct investment (FDI) clearance for the move.
The acquisition is positioned as a financially accretive step for Organigram, integrating a Sanity Group portfolio that generated positive EBITDA in 2025.